Join us at the American Heart Association meeting taking place from 10th to 13th November 2023 in Philadelphia, PA, USA.
Cardiomedex is very excited to be sharing the latest results confirming the clinical relevance of the diet-Induced Obese NASH Hamsterfor evaluating drugs targeting HFpEF
Cardiomedex will be presenting exciting results obtained on the unique HFpEF hamster model at the American Heart Association’s annual Scientific Sessions 2023 which will take place in Philadelphia, PA on November 11th-13th 2023.
These new results will be presented on Sunday November 12thduring the poster session “The Next Generation of Heart Failure Research” from 3:30-4:45PM (poster #2223) by Dr. Rana Assaly, Director of Scientific and Business Development at Cardiomedex.
This model shows severe heart failure with preserved ejection fraction (HFpEF) related to evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis and develops alterations in kidney function as characterized by our subsidiary company Physiogenex. This preclinical model provides a unique opportunity to evaluate the efficacy of drugs targeting HFpEF in a clinically relevant model.
Reach out to Rana Assaly during the AHA meeting to learn how Cardiomedex animal models and CRO services will drive your preclinical drug development to success.
Otherwise, contact us online to set-up an appointment with Dr. Assaly and/or discuss your drug development projects with us: